Your session is about to expire
← Back to Search
Pasireotide 200 mcg for Post-Bariatric Hypoglycemia (PASIPHY Trial)
PASIPHY Trial Summary
This trial will last for a maximum of 59 weeks for participants with post-bariatric hypoglycemia. It includes a Core Phase lasting 19 weeks with different stages such as screening,
PASIPHY Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPASIPHY Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 249 Patients • NCT02060383PASIPHY Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many individuals are currently enrolled in this research investigation?
"This clinical trial aims to enroll 72 qualifying participants. Eligible individuals have the opportunity to engage in this study at various locations, such as AP-HP Georges Pompidou European Hospital situated at 20 Leblanc Street in Paris, Texas and Clinical Research Solution: Endocrine and Psychiatry Center located on 9539 Huffmeister Road in Houston, Georgia."
Are there any available positions for patients in this ongoing clinical trial?
"Indeed, as outlined on clinicaltrials.gov, this investigation is presently in search of suitable participants. The trial was initially disclosed on January 4th, 2024 and underwent its most recent update on February 15th, 2024. There is a need to enroll a total of 72 individuals across 20 different sites for the study."
In how many locations is this trial currently being conducted?
"Enrollment is open for 20 participants at sites like AP-HP Hopital Europeen Georges Pompidou on Rue Leblanc in Paris, Clinical Research Solution: Endocrine and Psychiatry Center on Huffmeister Rd in Houston, and Georgia Clinical Research, LLC on Five Forks Trickum SW in Lawrenceville. Additionally, there are opportunities available at another 20 undisclosed locations."
Has Pasireotide 200 mcg received approval from the FDA?
"Based on Power's evaluation for this Phase 2 trial, Pasireotide at a dosage of 200 mcg has been rated as a safety level of 2."
Share this study with friends
Copy Link
Messenger